Archive · 12 Jan 2026
Australian Researchers Develop Targeted Therapy for Rare Blood Cancer
Australian scientists have found a new way to treat a rare and serious blood cancer called myelofibrosis.
This disease makes it hard for the body to produce healthy blood cells, causing tiredness, pain, and other problems.
Current treatments only help with symptoms, but don't cure the disease.
The researchers used immunotherapy to target the bad cells causing the disease, leaving the good cells alone.
They found two special targets that could help remove these bad cells.
This is a big step forward in treating myelofibrosis, but more research is needed before it can be used in patients.
Australian researchers developed a targeted immunotherapy approach for myelofibrosis, a rare blood cancer.
Current treatments only manage symptoms, but the new approach aims to target and remove the abnormal cells driving the disease.
The study identified two targets that could optimally remove the culprit cells.
The findings highlight the potential of precision immunology, which uses the immune system to target disease-causing cells while sparing healthy ones.
Further research and clinical development are needed before the approach can be tested in patients.
- Who
- Researchers from South Australian Health and Medical Research Institute (SAHMRI)
- What
- Developed a targeted therapeutic approach for myelofibrosis, a rare blood cancer
- When
- The research was published in the journal Blood
- Where
- Australia
- Why
- To improve treatment for myelofibrosis by targeting the abnormal cells driving the disease
- Disease
- Myelofibrosis
- Research Focus
- Targeted immunotherapy
- Key Findings
- Identified two targets for removing abnormal cells
- Research Team
- South Australian Health and Medical Research Institute (SAHMRI)
- Publication
- Journal Blood
- Future Steps
- Further research and clinical development needed
